TGA / PMDA / NMPA · Asia-Pacific
suspension — TGA / PMDA / NMPA regulatory status
suspension regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 170 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 0600-PG-PSC-218 | Phase 3 | Anaxis Pharma | 2025-521736-10-00 |
| 060018-PG-PSC-217 | Phase 3 | Anaxis Pharma | 2025-521709-42-00 |
| 2024/4031 | Phase 3 | George Institute for | 2024-520140-42-00 |
| 212496 | Phase 3 | GSK Glaxo Smith | 2024-512291-34-00 |
| 213997 (VNS 20-001) | Phase 3 | GSK Glaxo Smith | 2024-515868-31-00 |
| 213998 (VNS 20-002) | Phase 3 | GSK Glaxo Smith | 2024-515869-33-00 |
| 214002 (VNS 20-004) | Phase 3 | GSK Glaxo Smith | 2024-516635-27-00 |
| 217848 | Phase 3 | GSK Glaxo Smith | 2023-510196-59-00 |
| 219700 | Phase 3 | ViiV Healthcare Pty | 2023-503893-19-00 |
| 220030 | Phase 3 | GSK Glaxo Smith | 2024-519549-31-00 |
| 2215-CL-0201 | Phase 3 | Astellas Pharma | 2024-512474-98-00 |
| 221611 | Phase 3 | ViiV Healthcare Pty | 2024-515070-28-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2026106858 | FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES | WO |
| 2025114430 | COMPOSITION À LIBÉRATION MODIFIÉE | WO |
| 2025030001 | PROCÉDÉS ET COMPOSITIONS POUR LE MAINTIEN DE LA MOBILITÉ ET/OU DE LA MASSE DES MUSCLES SQUELETTIQUES, ET/OU POUR LA RÉCUPÉRATION DE LA FORCE DES MUSCLES SQUELETTIQUES | WO |
| 12201639 | Aqueous oral pharmaceutical suspension compositions | US |
| 2024206551 | COMPOSITIONS ET PROCÉDÉS DE RÉHYDRATATION D'ALGUES MARINES | WO |
| 2024064327 | OLIGOSACCHARIDES DE LAIT HUMAIN POUR AMÉLIORER LA FONCTION DE BARRIÈRE HÉMATO-ENCÉPHALIQUE | WO |
| 3256289 | MÉTHODES PERMETTANT DE FAVORISER LA CROISSANCE DE RATTRAPAGE SAINE | CA |
| 3249631 | PROCÉDÉS ET COMPOSITIONS POUR RALENTIR LE DÉVELOPPEMENT DU DIABÈTE OU RÉDUIRE UN RISQUE DE DIABÈTE | CA |
| 2023159093 | COMPOSITIONS NUTRITIONNELLES COMPRENANT DES OLIGOSACCHARIDES DE LAIT MATERNEL ET DE L'IMMUNOGLOBULINE BOVINE | WO |
| 2023158844 | COMPOSITIONS NUTRITIONNELLES EN POUDRE TRAITÉES THERMIQUEMENT ET PROCÉDÉS DE MAINTIEN DE (2S)-HESPÉRIDINE | WO |
| 2023141408 | BÊTA-HYDROXY BÊTA-MÉTHYLBUTYRATE ET FLAVONOÏDE D'AGRUME POUR FAVORISER LA RÉGÉNÉRATION MUSCULAIRE | WO |
| 2022226311 | COMPOSITIONS NUTRITIONNELLES COMPRENANT DES OLIGOSACCHARIDES DE LAIT HUMAIN ET UN CONSTITUANT LIPIDIQUE DÉSIGNÉ D'AMÉLIORATION DE FONCTION PULMONAIRE | WO |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of suspension?
suspension currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get suspension regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to suspension?
This spoke lists 170 published programs associated with suspension in our pipeline index.